Literature DB >> 8175711

Down-modulation of interleukin-6 gene expression by 17 beta-estradiol in the absence of high affinity DNA binding by the estrogen receptor.

A Ray1, K E Prefontaine, P Ray.   

Abstract

The mechanism of repression of the interleukin-6 (IL-6) promoter by 17 beta-estradiol (E2) was investigated in cells transfected with wild-type (wt) or mutant estrogen receptor (ER) expression vectors. In transient transfection experiments, IL-1-induced activation of the IL-6 promoter was efficiently inhibited by wt ER. However, estrogen receptors carrying mutations within or over-lapping with the DNA binding domain did not repress IL-6 promoter activity. A mutant receptor lacking the N-terminal transactivator function-1 but retaining the C-terminal transactivator function-2 also repressed activation of the IL-6 promoter. Our recent experiments indicate the requirement for both the nuclear factor (NF)-IL6 and the NF-kappa B sites in the IL-6 promoter for activation by IL-1. We now show that activation of the IL-6 promoter, elicited by a combination of NF-IL6 and the p65 subunit of NF-kappa B, can be inhibited by the wt receptor but not by a receptor containing a mutation in its DNA binding domain. Although a deletion within the DNA binding domain of ER abolished the repressor function of the receptor, a chimeric receptor ER-GR CAS1, in which the DNA binding domain of ER was swapped with the complementary region from the glucocorticoid receptor, retained the inhibitory effects on the IL-6 promoter. This was in contrast to the absolute dependence of ER on its own DNA binding domain for activation of typical estrogen response element-containing promoters, as reported previously by other investigators. Furthermore, the repression of the IL-6 promoter by a combination of ER and E2, unlike activation of estrogen response elements by the same combination, did not appear to be mediated via high affinity binding of the receptor to the promoter. In functional experiments, the transactivator function of ER was totally inhibited by overexpression of p65 and to a lesser extent by that of NF-IL6. These results indicate that ER may repress gene expression in the absence of high affinity DNA binding.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8175711

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  69 in total

1.  Genetic determinants of IL-6 expression levels do not influence bone loss in inflammatory bowel disease.

Authors:  C Schulte; H Goebell; H D Röher; K M Schulte
Journal:  Dig Dis Sci       Date:  2001-11       Impact factor: 3.199

2.  Effects of 17beta-estradiol on cytokine-induced endothelial cell adhesion molecule expression.

Authors:  T Caulin-Glaser; C A Watson; R Pardi; J R Bender
Journal:  J Clin Invest       Date:  1996-07-01       Impact factor: 14.808

3.  Regulation of the gp80 and gp130 subunits of the IL-6 receptor by sex steroids in the murine bone marrow.

Authors:  S C Lin; T Yamate; Y Taguchi; V Z Borba; G Girasole; C A O'Brien; T Bellido; E Abe; S C Manolagas
Journal:  J Clin Invest       Date:  1997-10-15       Impact factor: 14.808

Review 4.  Understanding sex biases in immunity: effects of estrogen on the differentiation and function of antigen-presenting cells.

Authors:  Greg Nalbandian; Susan Kovats
Journal:  Immunol Res       Date:  2005       Impact factor: 2.829

Review 5.  Aging of brain: role of estrogen.

Authors:  M K Thakur; P K Sharma
Journal:  Neurochem Res       Date:  2006-10-24       Impact factor: 3.996

Review 6.  Sex differences and estrogen modulation of the cellular immune response after injury.

Authors:  Melanie D Bird; John Karavitis; Elizabeth J Kovacs
Journal:  Cell Immunol       Date:  2008-02-21       Impact factor: 4.868

7.  Expression of an estrogen receptor agonist in differentiating osteoblast cultures.

Authors:  Thomas L McCarthy; Mary E Clough; Caren M Gundberg; Michael Centrella
Journal:  Proc Natl Acad Sci U S A       Date:  2008-05-12       Impact factor: 11.205

8.  Activation of farnesoid X receptor prevents atherosclerotic lesion formation in LDLR-/- and apoE-/- mice.

Authors:  Helen B Hartman; Stephen J Gardell; Chris J Petucci; Shuguang Wang; Julie A Krueger; Mark J Evans
Journal:  J Lipid Res       Date:  2009-01-27       Impact factor: 5.922

9.  In vivo modulation of murine serum tumour necrosis factor and interleukin-6 levels during endotoxemia by oestrogen agonists and antagonists.

Authors:  S H Zuckerman; N Bryan-Poole; G F Evans; L Short; A L Glasebrook
Journal:  Immunology       Date:  1995-09       Impact factor: 7.397

10.  Rifampicin Inhibits the LPS-induced Expression of Toll-like Receptor 2 via the Suppression of NF-kappaB DNA-binding Activity in RAW 264.7 Cells.

Authors:  Seong Keun Kim; Young Mi Kim; Chung Eun Yeum; Song-Hyo Jin; Gue Tae Chae; Seong-Beom Lee
Journal:  Korean J Physiol Pharmacol       Date:  2009-12-31       Impact factor: 2.016

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.